Literature DB >> 9342582

Use of albumin in two Spanish university hospitals.

E Vargas1, V de Miguel, A Portolés, C Avendaño, M I Ambit, A Torralba, A Moreno.   

Abstract

OBJECTIVES: The aim of this study was to characterize the use of seralbumin, evaluating how appropriate its prescription is and what possible economic repercussions may result from inappropriate use.
METHODS: We performed a prospective study that included all patients receiving albumin in two University Hospitals from October 1995 to March 1996. The reasons for albumin use were considered appropriate if they coincided with the recommendations of a panel of experts.
RESULTS: During the study period, 197 patients received albumin and a total of 3208 50-ml vials (20%) were used. The internal medicine and gastroenterology services prescribed this drug the most often. The most frequent prescription motives were paracentesis in cirrhotic patients (25.9%), hypoalbuminemia (24.9%) and chronic handling of cirrhotic patients (18.6%). Only 16 prescriptions (8.1%) (corresponding to 315 vials, 9.8%) were considered appropriate. One cause of inappropriate prescribing was that colloid solutions had not previously been used in 56 (30.9%) of the 186 inappropriate prescriptions. During the study period, 74,306 ECUs were spent on inappropriate indications.
CONCLUSIONS: The use of albumin in our centers is incorrect and has important economic repercussions. Some educational and informative measures must be established to change this situation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342582     DOI: 10.1007/s002280050320

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Pierluigi Berti; Francesco Bennardello; Francesco Fiorin; Pierluigi Piccoli
Journal:  Blood Transfus       Date:  2020-12-18       Impact factor: 3.443

3.  How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure.

Authors:  Federica Mirici-Cappa; Paolo Caraceni; Marco Domenicali; Ernesto Gelonesi; Barbara Benazzi; Giacomo Zaccherini; Franco Trevisani; Cristina Puggioli; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

4.  Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre-post design study.

Authors:  Farzaneh Zolfagharian; Saba Ghazanfari; Sepideh Elyasi; Paria Iraji; Mohammad Reza Saberi; Nasser Vahdati-Mashhadian; Amir Hooshang Mohammadpour
Journal:  Int J Clin Pharm       Date:  2017-05-24

5.  AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Giancarlo M Liumbruno; Francesco Bennardello; Pierluigi Piccoli; Claudio Velati
Journal:  Blood Transfus       Date:  2016-01       Impact factor: 3.443

6.  The evaluation of albumin utilization in a teaching university hospital in iran.

Authors:  Zahra Jahangard-Rafsanjani; Mohammad Reza Javadi; Hassan Torkamandi; Sara Alahyari; Azita Hajhossein Talasaz; Kheirollah Gholami
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Investigating the Use of Human Albumin in a Non-Teaching Hospital in Iran.

Authors:  Farzaneh Foroughinia; Shahriar Mazraie
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

8.  Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital.

Authors:  Afsaneh Vazin; Iman Karimzadeh; Razieh Karamikhah; Zahra Oveisi; Samaneh Mohseni; Maryam Keykhaee; Fatemeh Roshanfard; Elaheh Sabet; Asal Zargari-Samadnejad
Journal:  BMC Health Serv Res       Date:  2018-10-24       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.